Increase in Fibrinolytic Activity after Erythropoietin Therapy

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Thrombosis and Haemostasis

• Publication date

  1992-02-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0038-1648429PMID 1621253
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation.

  1990cited by this paper
• Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.

  1987cited by this paper
• Determination of tissue plasminogen activator and its "fast" inhibitor in plasma.

  1986cited by this paper

• Rebuttal to the Letter by T Exner and R. Dybkaer

  2018cites this paper
• Erythropoïétines et dopage : utilisations actuelles, nouvelles perspectives et méthodes de détection Erythropoietins and doping : uses, new perspectives and detection methods. A review

  2003cites this paper
• Erythropoietin use and abuse: When physiology and pharmacology collide.

  2001cites this paper
• Recombinant human erythropoietin treatment in chronic renal failure: effects on hemostasis and vasculature.

  2000cites this paper
• [Screening for exogenous erythropoietin].

  1999cites this paper
• Long-term effects of erythropoietin treatment on the coagulation system during standardized hemodialysis.

  1995cites this paper
• Effect of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant human erythropoietin

  1995cites this paper
• von Willebrand factor and rise in ristocetin co-factor with erythropoietin.

  1993cites this paper
• Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients.

  1993cites this paper
• von Willebrand factor and rise in ristocetin co-factor with erythropoietin.

  1993cites this paper
• von Willebrand factor and rise in ristocetin co-factor with erythropoietin.

  1993cites this paper
• Further Evidence that Alpha-Granule Components such as Platelet Factor 4 Are Involved in Platelet-IgG-Heparin Interactions during Heparin-Associated Thrombocytopenia

  1993cites this paper
• Erythropoietin Is Not a Cause of Access Thrombosis

  1993cites this paper
• rHuEPO lncreases Urinary Excretion of Fibrin Degradation Products in Haemodialysed Patients

  1993cites this paper
• Erythropoietin Doping in Athletes: Possible Detection Through Measurement of Fibrinolytic Products

  1992cites this paper